NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm Announces Eligibility for European Union Centralized Procedure for ND0612H, a Novel Treatment for Advanced Parkinson’s Disease
NeuroDerm Announces Enrollment in a Second Phase 2 Study of ND0612,
a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson’s Disease > Read More